NC
SNDX icon

nVerses Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

nVerses Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,600
Closed -$32.8K – 1359
2024
Q2 		$32.8K Buy
+1,600
New +$33.5K 0.02% 679

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

nVerses Capital's SNDX Position: Q3 2024 in Review

nVerses Capital sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 1,600 shares — an estimated $32.8K sold.

nVerses Capital first reported a position in SNDX in Q2 2024 and held it in 1 quarter. The position peaked at $32.8K in Q2 2024. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • nVerses Capital reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 1,600 Syndax Pharmaceuticals shares in Q3 2024, an estimated $32.8K.
  • nVerses Capital first reported a position in Syndax Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Syndax Pharmaceuticals position peaked at $32.8K in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.